Press Release Biocartis Group NV: Biocartis Partners with Lilly to Explore Biomarker Testing for NSCLC Patients using the Idylla™ Platform
2023年8月10日 - 2:00PM
Press Release Biocartis Group NV: Biocartis Partners with Lilly to
Explore Biomarker Testing for NSCLC Patients using the Idylla™
Platform
PRESS RELEASE: 10 August 2023, 07:00 CEST
Biocartis
Partners with
Lilly to Explore
Biomarker Testing for
NSCLC Patients
using
the
Idylla™
PlatformMechelen, Belgium, 2023 -
Biocartis Group NV (the ‘Company’ or ‘Biocartis’), a global
innovative molecular diagnostics company (Euronext Brussels: BCART)
today announced that they have entered into a new post-commercial
collaboration program with Lilly, a global pharmaceutical company.
This program will explore the advantages of adding the Biocartis
IdyllaTM Platform to a molecular diagnostics workflow in global
clinical labs via a study in hospitals across Spain. The focus will
be to understand how the Idylla™ Platform can contribute to a more
expeditious and comprehensive approach to identify targetable
alterations when compared to various current clinical workflows for
NSCLC patients.
Roger Moody, Chief Executive Officer of
Biocartis, commented: “I am pleased that Lilly shares our
commitment to address the need for faster identification of
eligible patients for targeted therapy.” He also added: “Despite
guidelines and reimbursement, patients, especially those in
community hospital settings, continue to receive treatment based on
incomplete or untimely biomarker results. Our collaboration with
Lilly supports our ambition to deliver results in time for all
patients, including those being treated in community-based
centers.”
The intention of the Lilly-sponsored study in Spain is that the
results will guide and improve US community-based diagnostic
workflows by the introduction of the Idylla platform. The outcome
data is expected to be presented in the fall of 2024.
Anthony
Sireci, MD,
MSC, Senior Vice
President, Clinical
Biomarker and
Diagnostics, Loxo
Oncology at Lilly,
added: “There is a need to improve the rates of
molecular profiling of lung cancer patients before first line
treatment decisions are made. One of the barriers to this are the
long turnaround times associated with send out testing. This study
aims to test the hypothesis that an in-house, rapid turnaround time
and easy to use assay will deliver actionable results to patients
and increase their likelihood of receiving biomarker-informed
therapies.”
----- END ----
More information: Investor Relations
Biocartise-mail ir@biocartis.comAbout
Biocartis
With its revolutionary and proprietary Idylla™
platform, Biocartis (Euronext Brussels: BCART) aspires to enable
personalized medicine for patients around the world through
universal access to molecular testing, by making molecular testing
actionable, convenient, fast and suitable for any lab. The Idylla™
platform is a fully automated sample-to-result, real-time PCR
(Polymerase Chain Reaction) based system designed to offer in-house
access to accurate molecular information in a minimum amount of
time for faster, informed treatment decisions. Idylla™'s
continuously expanding menu of molecular diagnostic tests address
key unmet clinical needs, with a focus in oncology. This is the
fastest growing segment of the molecular diagnostics market
worldwide. Today, Biocartis offers tests supporting melanoma,
colorectal, lung and liver cancer, as well as for COVID-19 and
sepsis. More information: www.biocartis.com. Follow us on
Twitter: @Biocartis_.
Biocartis and Idylla™ are registered trademarks
in Europe, the United States and other countries. The Biocartis and
Idylla™ trademark and logo are used trademarks owned by Biocartis.
Please refer to the product labeling for applicable intended uses
for each individual Biocartis product.
This press release is not for distribution,
directly or indirectly, in any jurisdiction where to do so would be
unlawful. Any persons reading this press release should inform
themselves of and observe any such restrictions. Biocartis takes no
responsibility for any violation of any such restrictions by any
person. This press release does not constitute an offer or
invitation for the sale or purchase of securities in any
jurisdiction. No securities of Biocartis may be offered or sold in
the United States of America absent registration with the United
States Securities and Exchange Commission or an exemption from
registration under the U.S. Securities Act of 1933, as amended.
Forward-looking statements
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company's or,
as appropriate, the Company directors' or managements' current
expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity,
performance, prospects, growth, strategies and the industry in
which the Company operates. By their nature, forward-looking
statements involve a number of risks, uncertainties, assumptions
and other factors that could cause actual results or events to
differ materially from those expressed or implied by the
forward-looking statements. These risks, uncertainties, assumptions
and factors could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development.
Forward-looking statements contained in this press release
regarding past trends or activities are not guarantees of future
performance and should not be taken as a representation that such
trends or activities will continue in the future. In addition, even
if actual results or developments are consistent with the
forward-looking statements contained in this press release, those
results or developments may not be indicative of results or
developments in future periods. No representations and warranties
are made as to the accuracy or fairness of such forward-looking
statements. As a result, the Company expressly disclaims any
obligation or undertaking to release any updates or revisions to
any forward-looking statements in this press release as a result of
any change in expectations or any change in events, conditions,
assumptions or circumstances on which these forward-looking
statements are based, except if specifically required to do so by
law or regulation. Neither the Company nor its advisers or
representatives nor any of its subsidiary undertakings or any such
person's officers or employees guarantees that the assumptions
underlying such forward-looking statements are free from errors nor
does either accept any responsibility for the future accuracy of
the forward-looking statements contained in this press release or
the actual occurrence of the forecasted developments. You should
not place undue reliance on forward-looking statements, which speak
only as of the date of this press release.
Biocartis Group NV (EU:BCART)
過去 株価チャート
から 4 2024 まで 5 2024
Biocartis Group NV (EU:BCART)
過去 株価チャート
から 5 2023 まで 5 2024